marketcaparena
Search

    RIGL

    RIGEL PHARMACEUTICALS INC

    Company overview

    Market capitalization
    $922.04M
    Employees
    172
    Latest publication
    2026-09-29
    About RIGEL PHARMACEUTICALS INC

    Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue58,818,000USD69,802,000USD69,462,000USD101,685,000USD53,333,000USD57,596,000USD55,307,000USD36,841,000USD
    Cost Of Revenue4,606,000USD5,955,000USD4,753,000USD4,504,000USD4,409,000USD5,789,000USD8,026,000USD2,807,000USD
    Gross Profit54,212,000USD63,847,000USD64,709,000USD97,181,000USD48,924,000USD51,807,000USD47,281,000USD34,034,000USD
    Research Development11,676,000USD10,685,000USD7,353,000USD6,821,000USD8,436,000USD5,632,000USD6,182,000USD5,540,000USD
    Selling General Administrative30,651,000USD29,992,000USD28,936,000USD29,257,000USD27,715,000USD29,520,000USD27,043,000USD28,047,000USD
    Total Operating Expenses42,327,000USD40,677,000USD36,289,000USD36,078,000USD36,151,000USD35,152,000USD33,225,000USD33,587,000USD
    Operating Income11,885,000USD23,170,000USD28,420,000USD61,103,000USD12,773,000USD16,655,000USD14,056,000USD447,000USD
    Interest Income1,205,000USD1,243,000USD1,094,000USD753,000USD591,000USD522,000USD425,000USD552,000USD
    Interest Expense1,433,000USD1,699,000USD1,894,000USD1,874,000USD1,853,000USD1,955,000USD2,060,000USD2,029,000USD
    Net Interest Income-228,000USD-456,000USD-800,000USD-1,121,000USD-1,262,000USD-1,433,000USD-1,635,000USD-1,477,000USD
    Income Before Tax11,657,000USD22,714,000USD27,620,000USD59,982,000USD11,511,000USD15,222,000USD12,421,000USD-1,030,000USD
    Income Tax Expense3,003,000USD-245,351,000USD-280,000USD369,000USD65,000USD881,000USD——
    Tax Provision3,003,000USD-245,351,000USD-280,000USD369,000USD65,000USD——0USD
    Net Income8,654,000USD268,065,000USD27,900,000USD59,613,000USD11,446,000USD14,341,000USD12,421,000USD-1,030,000USD
    Net Income From Continuing Ops8,654,000USD268,065,000USD27,900,000USD59,613,000USD11,446,000USD14,341,000USD12,421,000USD-1,030,000USD
    Ebit13,090,000USD24,413,000USD29,514,000USD61,856,000USD13,364,000USD17,177,000USD14,481,000USD999,000USD
    Ebitda13,687,000USD25,014,000USD30,117,000USD62,463,000USD13,968,000USD17,781,000USD15,092,000USD1,612,000USD
    Depreciation And Amortization597,000USD601,000USD603,000USD607,000USD604,000USD604,000USD611,000USD613,000USD
    Reconciled Depreciation597,000USD601,000USD603,000USD607,000USD604,000USD604,000USD611,000USD613,000USD
    Total Other Income Expense Net-228,000USD-456,000USD-800,000USD-1,121,000USD-1,262,000USD-1,433,000USD-1,635,000USD-1,477,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20132013-12-31 · USDFY 20112011-12-31 · USDFY 20102010-12-31 · USD
    Total Revenue294,282,000USD179,278,000USD149,236,000USD108,621,000USD59,288,000USD7,150,000USD4,750,000USD125,000,000USD
    Cost Of Revenue19,621,000USD18,647,000USD1,083,000USD895,000USD906,000USD75,328,000USD89,163,000USD88,366,000USD
    Gross Profit274,661,000USD160,631,000USD148,153,000USD107,726,000USD58,382,000USD-68,178,000USD4,750,000USD125,000,000USD
    Research Development33,295,000USD23,380,000USD65,237,000USD60,101,000USD52,885,000USD75,328,000USD69,350,000USD64,392,000USD
    Selling General Administrative115,900,000USD113,059,000USD91,891,000USD76,598,000USD74,588,000USD19,612,000USD21,768,000USD25,291,000USD
    Total Operating Expenses149,195,000USD136,439,000USD160,649,000USD136,699,000USD127,473,000USD96,619,000USD91,118,000USD89,683,000USD
    Operating Income125,466,000USD24,192,000USD-12,496,000USD-28,973,000USD-69,091,000USD-89,469,000USD-86,368,000USD35,317,000USD
    Interest Income3,681,000USD2,092,000USD47,000USD582,000USD2,532,000USD———
    Interest Expense7,320,000USD7,918,000USD4,860,000USD1,353,000USD335,000USD16,000USD25,000USD91,000USD
    Net Interest Income-3,639,000USD-5,826,000USD-4,813,000USD-771,000USD2,197,000USD———
    Income Before Tax121,827,000USD18,366,000USD-17,309,000USD-29,744,000USD-66,894,000USD-89,027,000USD-85,973,000USD37,890,000USD
    Income Tax Expense-245,197,000USD881,000USD605,000USD647,000USD-348,000USD0USD420,000USD91,000USD
    Tax Provision-245,197,000USD881,000USD605,000USD0USD————
    Net Income367,024,000USD17,485,000USD-17,914,000USD-29,744,000USD-66,546,000USD-89,027,000USD-85,973,000USD37,890,000USD
    Net Income From Continuing Ops367,024,000USD17,485,000USD-17,914,000USD-29,744,000USD-66,894,000USD-89,027,000USD-85,973,000USD—
    Ebit129,147,000USD26,284,000USD-12,449,000USD-28,391,000USD-66,559,000USD-87,790,000USD-85,948,000USD37,981,000USD
    Ebitda131,562,000USD28,512,000USD-11,287,000USD-27,685,000USD-65,876,000USD-85,198,000USD-83,993,000USD39,298,000USD
    Depreciation And Amortization2,415,000USD2,228,000USD1,162,000USD706,000USD683,000USD2,592,000USD1,955,000USD1,317,000USD
    Reconciled Depreciation2,415,000USD2,228,000USD1,162,000USD706,000USD683,000USD———
    Total Other Income Expense Net-3,639,000USD-5,826,000USD-4,813,000USD-771,000USD2,197,000USD442,000USD395,000USD2,573,000USD
    Unclassified Operating Expenses——3,521,000USD——1,679,000USD——
    Non Operating Income Net Other——47,000USD582,000USD2,532,000USD442,000USD420,000USD—
    Net Income Applicable To Common Shares——-17,914,000USD-29,744,000USD-66,894,000USD-89,027,000USD-85,973,000USD37,890,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets504,608,000USD513,594,000USD242,534,000USD206,736,000USD175,972,000USD163,976,000USD139,419,000USD128,408,000USD
    Intangible Assets24,160,000USD24,748,000USD25,336,000USD25,924,000USD26,512,000USD27,100,000USD27,687,000USD28,275,000USD
    Other Current Assets25,746,000USD21,942,000USD11,248,000USD16,684,000USD23,258,000USD10,165,000USD9,994,000USD8,658,000USD
    Total Liab104,711,000USD122,114,000USD124,925,000USD124,802,000USD157,405,000USD160,688,000USD154,055,000USD158,322,000USD
    Total Stockholder Equity399,897,000USD391,480,000USD117,609,000USD81,934,000USD18,567,000USD3,288,000USD-14,636,000USD-29,914,000USD
    Other Current Liab54,505,000USD60,265,000USD60,199,000USD25,611,000USD46,049,000USD24,608,000USD48,676,000USD50,525,000USD
    Common Stock18,000USD18,000USD18,000USD18,000USD18,000USD18,000USD17,000USD17,000USD
    Capital Stock18,000USD18,000USD18,000USD18,000USD18,000USD18,000USD17,000USD17,000USD
    Retained Earnings-1,014,387,000USD-1,023,041,000USD-1,291,106,000USD-1,319,006,000USD-1,378,619,000USD-1,390,065,000USD-1,404,406,000USD-1,416,827,000USD
    Cash24,411,000USD40,580,000USD48,534,000USD53,407,000USD45,728,000USD56,746,000USD51,692,000USD36,053,000USD
    Cash And Short Term Investments146,684,000USD154,955,000USD137,143,000USD108,379,000USD77,099,000USD77,321,000USD61,114,000USD49,102,000USD
    Total Current Assets234,027,000USD240,166,000USD214,927,000USD175,393,000USD146,563,000USD135,103,000USD106,467,000USD94,723,000USD
    Total Current Liabilities89,492,000USD99,237,000USD94,400,000USD86,636,000USD66,629,000USD63,299,000USD54,312,000USD58,649,000USD
    Net Debt21,309,000USD12,723,000USD12,346,000USD7,637,000USD15,338,000USD3,219,000USD8,536,000USD24,278,000USD
    Short Term Debt30,501,000USD30,426,000USD30,355,000USD22,878,000USD15,271,000USD7,557,000USD466,000USD639,000USD
    Short Long Term Debt29,865,000USD29,812,000USD29,761,000USD22,361,000USD14,815,000USD7,272,000USD——
    Short Long Term Debt Total45,720,000USD53,303,000USD60,880,000USD61,044,000USD61,066,000USD59,965,000USD60,228,000USD60,331,000USD
    Long Term Debt14,991,000USD22,482,000USD29,969,000USD37,452,000USD44,931,000USD52,408,000USD59,762,000USD59,692,000USD
    Short Term Investments122,273,000USD114,375,000USD88,609,000USD54,972,000USD31,371,000USD20,575,000USD9,422,000USD13,049,000USD
    Net Receivables49,945,000USD51,763,000USD45,925,000USD39,907,000USD41,547,000USD41,615,000USD30,575,000USD28,904,000USD
    Inventory11,652,000USD11,506,000USD20,611,000USD10,423,000USD4,659,000USD6,002,000USD4,784,000USD8,059,000USD
    Accounts Payable4,486,000USD7,191,000USD3,846,000USD7,290,000USD3,954,000USD3,339,000USD3,815,000USD6,130,000USD
    Property Plant Equipment Net785,000USD920,000USD1,104,000USD1,235,000USD1,381,000USD338,000USD504,000USD675,000USD
    Property Plant Equipment Gross785,000USD920,000USD1,104,000USD1,235,000USD1,381,000USD599,000USD504,000USD675,000USD
    Accumulated Other Comprehensive Income-128,000USD181,000USD95,999USD6,000USD-2,000USD10,000USD11,000USD-9,000USD
    Common Stock Shares Outstanding19,686,000shares18,840,000shares19,156,000shares18,162,000shares18,169,000shares17,986,000shares17,648,000shares17,549,000shares
    Non Current Assets Total270,581,000USD273,428,000USD27,607,000USD31,343,000USD29,409,000USD28,873,000USD32,952,000USD33,685,000USD
    Non Current Liabilities Total15,218,999USD22,877,000USD30,524,999USD38,166,000USD90,776,000USD97,389,000USD99,743,000USD99,673,000USD
    Non Currrent Assets Other2,357,000USD1,908,000USD1,167,000USD4,184,000USD1,516,000USD1,435,000USD4,761,000USD4,735,000USD
    Net Working Capital144,535,000USD140,929,000USD120,527,000USD88,757,000USD79,934,000USD71,804,000USD52,155,000USD36,074,000USD
    Unclassified Non Current Assets243,279,000USD245,852,000USD——————
    Unclassified Current Liabilities-29,865,000USD-29,812,000USD-31,116,000USD-22,361,000USD-14,815,000USD-7,272,000USD——
    Unclassified Equity1,414,376,000USD1,414,304,000USD1,408,583,001USD1,400,898,000USD1,397,152,000USD1,393,307,000USD1,389,725,000USD1,386,888,000USD
    Current Deferred Revenue—1,355,000USD1,355,000USD30,857,000USD1,355,000USD27,795,000USD1,355,000USD1,355,000USD
    Non Current Liabilities Other————44,981,000USD44,981,000USD39,981,000USD39,981,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets513,594,000USD163,976,000USD117,225,000USD134,279,000USD167,328,000USD110,378,000USD147,569,000USD139,109,000USD
    Intangible Assets24,748,000USD27,100,000USD13,878,000USD14,949,000USD————
    Other Current Assets21,942,000USD10,165,000USD6,261,000USD8,259,000USD7,412,000USD14,045,000USD9,462,000USD6,958,000USD
    Total Liab122,114,000USD160,688,000USD145,869,000USD147,895,000USD136,954,000USD76,352,000USD93,754,000USD29,232,000USD
    Total Stockholder Equity391,480,000USD3,288,000USD-28,644,000USD-13,616,000USD30,374,000USD34,026,000USD53,815,000USD109,877,000USD
    Other Current Liab60,265,000USD24,608,000USD21,165,000USD28,056,000USD39,356,000USD25,495,000USD21,500,000USD20,313,000USD
    Common Stock18,000USD18,000USD17,000USD174,000USD172,000USD169,000USD168,000USD167,000USD
    Capital Stock18,000USD18,000USD175,000USD174,000USD172,000USD169,000USD168,000USD167,000USD
    Retained Earnings-1,023,041,000USD-1,390,065,000USD-1,407,550,000USD-1,382,459,000USD-1,323,886,000USD-1,305,972,000USD-1,276,228,000USD-1,209,334,000USD
    Cash40,580,000USD56,746,000USD32,786,000USD24,459,000USD18,890,000USD30,373,000USD22,521,000USD76,322,000USD
    Cash And Short Term Investments154,955,000USD77,321,000USD56,933,000USD58,206,000USD124,967,000USD57,327,000USD98,078,000USD128,537,000USD
    Total Current Assets240,166,000USD135,103,000USD99,266,000USD115,903,000USD154,467,000USD88,983,000USD119,005,000USD136,987,000USD
    Total Current Liabilities99,237,000USD63,299,000USD53,267,000USD65,211,000USD63,554,000USD40,841,000USD58,212,000USD27,734,000USD
    Current Deferred Revenue1,355,000USD27,795,000USD17,039,000USD13,514,000USD10,511,000USD3,018,000USD25,288,000USD1,030,000USD
    Net Debt12,723,000USD3,219,000USD27,793,000USD17,094,000USD11,675,000USD8,714,000USD13,791,000USD-76,322,000USD
    Short Term Debt30,426,000USD7,557,000USD7,921,000USD1,133,000USD9,892,000USD8,621,000USD7,272,000USD—
    Short Long Term Debt29,812,000USD7,272,000USD7,229,000USD—————
    Short Long Term Debt Total53,303,000USD59,965,000USD60,579,000USD41,553,000USD30,565,000USD39,087,000USD36,312,000USD—
    Long Term Debt22,482,000USD52,408,000USD52,373,000USD39,448,000USD19,914,000USD19,815,000USD9,810,000USD—
    Short Term Investments114,375,000USD20,575,000USD24,147,000USD33,747,000USD106,077,000USD26,954,000USD75,557,000USD52,215,000USD
    Net Receivables51,763,000USD41,615,000USD30,550,000USD40,320,000USD15,472,000USD15,973,000USD10,111,000USD4,077,000USD
    Inventory11,506,000USD6,002,000USD5,522,000USD9,118,000USD6,616,000USD1,638,000USD1,354,000USD894,000USD
    Accounts Payable7,191,000USD3,339,000USD7,142,000USD22,508,000USD3,795,000USD3,707,000USD4,152,000USD6,391,000USD
    Property Plant Equipment Net920,000USD338,000USD1,026,000USD2,787,000USD11,887,000USD20,571,000USD27,868,000USD1,387,000USD
    Property Plant Equipment Gross920,000USD599,000USD2,730,000USD13,594,000USD26,438,000USD20,571,000USD27,868,000USD1,387,000USD
    Accumulated Other Comprehensive Income181,000USD10,000USD8,000USD-153,000USD-102,000USD-4,000USD23,000USD-24,000USD
    Common Stock Shares Outstanding18,840,000shares17,687,000shares17,401,000shares17,240,600shares17,049,200shares16,875,400shares16,740,000shares16,053,000shares
    Non Current Assets Total273,428,000USD28,873,000USD17,959,000USD18,376,000USD12,861,000USD21,395,000USD28,564,000USD2,122,000USD
    Non Current Liabilities Total22,877,000USD97,389,000USD92,602,000USD82,684,000USD73,400,000USD35,511,000USD35,542,000USD1,498,000USD
    Non Currrent Assets Other1,908,000USD1,435,000USD3,055,000USD640,000USD974,000USD824,000USD696,000USD735,000USD
    Net Working Capital140,929,000USD71,804,000USD45,999,000USD50,692,000USD90,913,000USD48,142,000USD60,793,000USD109,253,000USD
    Unclassified Non Current Assets245,852,000USD———————
    Unclassified Current Liabilities-29,812,000USD-7,272,000USD-7,229,000USD—————
    Unclassified Equity1,414,304,000USD1,393,307,000USD1,378,706,000USD1,368,648,000USD1,354,018,000USD1,339,664,000USD1,329,684,000USD1,318,901,000USD
    Non Current Liabilities Other—44,981,000USD39,944,000USD43,236,000USD52,727,000USD5,045,000USD5,098,000USD—
    Other Assets———640,000USD974,000USD824,000USD696,000USD735,000USD
    Net Tangible Assets———-28,565,000USD30,374,000USD44,677,000USD74,449,000USD111,285,000USD
    Other Liab————52,727,000USD5,045,000USD6,502,000USD1,498,000USD
    Unclassified Non Current Liabilities————-51,968,000USD5,606,000USD14,132,000USD—
    Deferred Long Term Liab———————90,000USD
    Unclassified Current Assets———————-3,479,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income8,654,000USD268,065,000USD27,900,000USD59,613,000USD11,446,000USD14,341,000USD12,421,000USD-1,030,000USD
    Depreciation597,000USD601,000USD603,000USD607,000USD604,000USD604,000USD611,000USD613,000USD
    Stock Based Compensation3,456,000USD2,748,000USD3,363,000USD3,276,000USD3,324,000USD2,087,000USD2,644,000USD2,528,000USD
    Other Non Cash Items-170,000USD-246,095,000USD-467,000USD-40,231,000USD-190,000USD-332,000USD-92,000USD-159,000USD
    Change To Account Receivables1,818,000USD-5,838,000USD-6,018,000USD1,640,000USD68,000USD-11,040,000USD-1,671,000USD-1,392,000USD
    Change To Inventory-581,000USD1,131,000USD188,000USD-8,367,000USD1,413,000USD1,925,000USD3,344,000USD-2,195,000USD
    Change In Working Capital-12,385,000USD-3,339,000USD-7,368,000USD7,272,000USD-16,077,000USD-2,197,000USD6,095,000USD-1,650,000USD
    Total Cash From Operating Activities2,725,000USD21,980,000USD24,031,000USD30,537,000USD-893,000USD14,503,000USD21,679,000USD302,000USD
    Capital Expenditures0USD-12,000USD-12,000USD0USD0USD-26,000USD-10,000USD-222,000USD
    Free Cash Flow2,725,000USD21,992,000USD24,019,000USD30,537,000USD-893,000USD14,477,000USD21,669,000USD80,000USD
    Investments-7,975,000USD-25,374,000USD-33,175,000USD-23,276,000USD-10,552,000USD-10,914,000USD3,802,000USD10,929,000USD
    Total Cashflows From Investing Activities-7,975,000USD-25,362,000USD-33,175,000USD-23,276,000USD-10,552,000USD-10,914,000USD3,802,000USD10,929,000USD
    Net Borrowings-7,500,000USD———0USD0USD0USD—
    Total Cash From Financing Activities-10,919,000USD-4,572,000USD4,271,000USD418,000USD484,000USD1,465,000USD-9,842,000USD-752,000USD
    Sale Purchase Of Stock-3,740,000USD———0USD———
    Change In Cash-16,169,000USD-7,954,000USD-4,873,000USD7,679,000USD-10,961,000USD5,054,000USD15,639,000USD10,479,000USD
    Begin Period Cash Flow40,637,000USD48,591,000USD53,464,000USD45,785,000USD56,746,000USD51,692,000USD36,053,000USD25,574,000USD
    End Period Cash Flow24,468,000USD40,637,000USD48,591,000USD53,464,000USD45,785,000USD56,746,000USD51,692,000USD36,053,000USD
    Other Cashflows From Financing Activities-10,919,000USD-7,500,000USD4,271,000USD-484,000USD484,000USD1,465,000USD-9,842,000USD-752,000USD
    Unclassified Operating Cash Flow2,573,000USD———————
    Unclassified Financing Cash Flow11,240,000USD2,928,000USD——————
    Other Cashflows From Investing Activities—12,000USD-12,000USD——72,000USD26,000USD10,929,000USD
    Unclassified Investing Cash Flow———————-10,707,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income367,024,000USD17,485,000USD-25,091,000USD-58,573,000USD-17,914,000USD-29,744,000USD-66,894,000USD-70,480,000USD
    Depreciation2,415,000USD2,228,000USD1,238,000USD998,000USD1,162,000USD706,000USD683,000USD594,000USD
    Stock Based Compensation12,711,000USD12,393,000USD8,806,000USD12,385,000USD9,486,000USD7,297,000USD9,115,000USD7,704,000USD
    Other Non Cash Items-41,131,000USD-788,000USD-213,000USD481,000USD3,426,000USD-122,000USD-1,073,000USD-766,000USD
    Change To Account Receivables-10,148,000USD-11,065,000USD9,770,000USD-24,848,000USD501,000USD-5,862,000USD-6,034,000USD-4,077,000USD
    Change To Inventory-5,635,000USD764,000USD1,172,000USD-2,377,000USD-4,875,000USD-126,000USD-366,000USD-839,000USD
    Change In Working Capital-19,512,000USD153,000USD9,517,000USD-29,049,000USD9,718,000USD-30,322,000USD16,659,000USD4,122,000USD
    Total Cash From Operating Activities75,655,000USD31,471,000USD-5,743,000USD-73,758,000USD5,878,000USD-52,185,000USD-41,510,000USD-58,826,000USD
    Capital Expenditures0USD-396,000USD-15,000,000USD-450,000USD-627,000USD-1,262,000USD-1,455,000USD-1,106,000USD
    Free Cash Flow75,655,000USD31,075,000USD-20,743,000USD-74,208,000USD5,251,000USD-53,447,000USD-42,965,000USD-59,932,000USD
    Investments-92,365,000USD4,130,000USD21,175,000USD72,334,000USD-79,409,000USD48,728,000USD-22,201,000USD26,070,000USD
    Total Cashflows From Investing Activities-92,365,000USD4,130,000USD-4,297,000USD72,777,000USD-80,036,000USD47,466,000USD-23,656,000USD24,964,000USD
    Net Borrowings-7,500,000USD0USD19,950,000USD19,542,000USD19,542,000USD9,975,000USD9,789,000USD9,789,000USD
    Total Cash From Financing Activities601,000USD-11,641,000USD18,367,000USD6,550,000USD62,675,000USD12,571,000USD11,365,000USD71,894,000USD
    Sale Purchase Of Stock0USD-10,000,000USD0USD2,124,000USD4,775,000USD2,596,000USD1,576,000USD71,894,000USD
    Change In Cash-16,109,000USD23,960,000USD8,327,000USD5,569,000USD-11,483,000USD7,852,000USD-53,801,000USD38,032,000USD
    Begin Period Cash Flow56,746,000USD32,786,000USD24,459,000USD18,890,000USD30,373,000USD22,521,000USD76,322,000USD38,290,000USD
    End Period Cash Flow40,637,000USD56,746,000USD32,786,000USD24,459,000USD18,890,000USD30,373,000USD22,521,000USD76,322,000USD
    Other Cashflows From Financing Activities601,000USD-1,641,000USD-1,583,000USD-12,992,000USD62,675,000USD2,596,000USD1,576,000USD4,732,000USD
    Unclassified Operating Cash Flow-245,852,000USD———————
    Unclassified Financing Cash Flow7,500,000USD——-2,124,000USD-24,317,000USD-2,596,000USD-1,576,000USD-14,521,000USD
    Other Cashflows From Investing Activities—98,000USD259,000USD893,000USD-627,000USD-1,262,000USD-1,455,000USD-1,106,000USD
    Unclassified Investing Cash Flow——-10,731,000USD——1,262,000USD1,455,000USD1,106,000USD
    Change To Liabilities———-3,541,000USD-381,000USD3,422,000USD-1,053,000USD11,089,000USD
    Cash And Cash Equivalents Changes———5,569,000USD-11,483,000USD7,852,000USD-53,801,000USD38,032,000USD
    Issuance Of Capital Stock—————0USD2,896,000USD67,162,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductDevelopment Milestones0USD0001034842-26-000032
    Q1 2026Quarterly · 2026-03-31ProductDiscounts And Allowances-20,465,000USD0001034842-26-000032
    Q1 2026Quarterly · 2026-03-31ProductGross Product75,388,000USD0001034842-26-000032
    Q1 2026Quarterly · 2026-03-31ProductOther2,095,000USD0001034842-26-000032
    Q1 2026Quarterly · 2026-03-31ProductRoyalty1,800,000USD0001034842-26-000032
    FY 2025Yearly · 2025-12-31ProductContract Revenues From Collaborations — Development Milestones3,000,000USD0001034842-26-000015
    FY 2025Yearly · 2025-12-31ProductContract Revenues From Collaborations — Release Of Share Cost Liability39,981,000USD0001034842-26-000015
    FY 2025Yearly · 2025-12-31ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others19,053,000USD0001034842-26-000015
    FY 2025Yearly · 2025-12-31ProductDiscounts And Allowances-77,978,000USD0001034842-26-000015
    FY 2025Yearly · 2025-12-31ProductGovernment Contract265,000USD0001034842-26-000015
    FY 2025Yearly · 2025-12-31ProductGross Product309,961,000USD0001034842-26-000015
    FY 2025Yearly · 2025-12-31ProductLicense0USD0001034842-26-000015
    Q2 2025Quarterly · 2025-06-30ProductContract Revenues From Collaborations — Release Of Cost Share Liability39,981,000USD0001558370-25-010281
    Q2 2025Quarterly · 2025-06-30ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others2,756,000USD0001558370-25-010281
    Q2 2025Quarterly · 2025-06-30ProductDiscounts And Allowances-20,744,000USD0001558370-25-010281
    Q2 2025Quarterly · 2025-06-30ProductGross Product79,692,000USD0001558370-25-010281
    Q1 2025Quarterly · 2025-03-31ProductContract Revenues From Collaborations — Development Milestones3,000,000USD0001558370-25-006493
    Q1 2025Quarterly · 2025-03-31ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others6,783,000USD0001558370-25-006493
    Q1 2025Quarterly · 2025-03-31ProductDiscounts And Allowances-16,642,000USD0001558370-25-006493
    Q1 2025Quarterly · 2025-03-31ProductGross Product60,192,000USD0001558370-25-006493
    FY 2024Yearly · 2024-12-31ProductContract Revenues From Collaborations — License14,000,000USD0001034842-26-000015
    FY 2024Yearly · 2024-12-31ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others20,376,000USD0001034842-26-000015
    FY 2024Yearly · 2024-12-31ProductDevelopment Milestones0USD0001034842-26-000015
    FY 2024Yearly · 2024-12-31ProductDiscounts And Allowances-65,022,000USD0001034842-26-000015
    FY 2024Yearly · 2024-12-31ProductGovernment Contract0USD0001034842-26-000015
    FY 2024Yearly · 2024-12-31ProductGross Product209,924,000USD0001034842-26-000015
    FY 2024Yearly · 2024-12-31ProductRelease Of Share Cost Liability0USD0001034842-26-000015
    Q3 2024Quarterly · 2024-09-30ProductContract Revenues From Collaborations — License10,000,000USD0001104659-25-106268
    Q3 2024Quarterly · 2024-09-30ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others6,380,000USD0001104659-25-106268
    Q3 2024Quarterly · 2024-09-30ProductDiscounts And Allowances-17,395,000USD0001104659-25-106268
    Q3 2024Quarterly · 2024-09-30ProductGross Product56,322,000USD0001104659-25-106268
    FY 2023Yearly · 2023-12-31ProductContract Revenues From Collaborations — Development Milestones75,000USD0001034842-26-000015
    FY 2023Yearly · 2023-12-31ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others11,413,000USD0001034842-26-000015
    FY 2023Yearly · 2023-12-31ProductDiscounts And Allowances-42,764,000USD0001034842-26-000015
    FY 2023Yearly · 2023-12-31ProductGovernment Contract1,100,000USD0001034842-26-000015
    FY 2023Yearly · 2023-12-31ProductGross Product147,058,000USD0001034842-26-000015
    FY 2023Yearly · 2023-12-31ProductLicense0USD0001034842-26-000015
    FY 2023Yearly · 2023-12-31ProductRelease Of Share Cost Liability0USD0001034842-26-000015
    Q3 2023Quarterly · 2023-09-30ProductContract Revenues From Collaborations — Development Milestones75,000USD0001558370-24-014862
    Q3 2023Quarterly · 2023-09-30ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others930,000USD0001558370-24-014862
    Q3 2023Quarterly · 2023-09-30ProductDiscounts And Allowances-11,456,000USD0001558370-24-014862
    Q3 2023Quarterly · 2023-09-30ProductGross Product38,585,000USD0001558370-24-014862
    FY 2022Yearly · 2022-12-31ProductContract Revenues From Collaborations — Development Milestones25,000,000USD0001558370-23-003035
    FY 2022Yearly · 2022-12-31ProductContract Revenues From Collaborations — License7,932,000USD0001558370-23-003035
    FY 2022Yearly · 2022-12-31ProductContract Revenues From Collaborations — Research And Development Services And Others6,092,000USD0001558370-23-003035
    FY 2022Yearly · 2022-12-31ProductDiscounts And Allowances-31,805,000USD0001558370-23-003035
    FY 2022Yearly · 2022-12-31ProductGovernment Contract4,500,000USD0001558370-23-003035
    FY 2022Yearly · 2022-12-31ProductGross Product108,523,000USD0001558370-23-003035
    FY 2022Yearly · 2022-12-31ProductRezlidhia900,000USD0001558370-23-003035
    Q2 2022Quarterly · 2022-06-30ProductContract Revenues From Collaborations — Development Milestones5,000,000USD0001558370-23-012722
    Q2 2022Quarterly · 2022-06-30ProductContract Revenues From Collaborations — License2,337,000USD0001558370-23-012722
    Q2 2022Quarterly · 2022-06-30ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others3,932,000USD0001558370-23-012722
    Q2 2022Quarterly · 2022-06-30ProductDiscounts And Allowances-7,877,000USD0001558370-23-012722
    Q2 2022Quarterly · 2022-06-30ProductGross Product26,427,000USD0001558370-23-012722
    Q1 2022Quarterly · 2022-03-31ProductContract Revenues From Collaborations — License208,000USD0001558370-23-007653
    Q1 2022Quarterly · 2022-03-31ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others330,000USD0001558370-23-007653
    Q1 2022Quarterly · 2022-03-31ProductDiscounts And Allowances-6,421,000USD0001558370-23-007653
    Q1 2022Quarterly · 2022-03-31ProductGross Product22,618,000USD0001558370-23-007653
    FY 2021Yearly · 2021-12-31ProductContract Revenues From Collaborations — Development Milestones1,875,000USD0001558370-24-002475
    FY 2021Yearly · 2021-12-31ProductContract Revenues From Collaborations — License70,553,000USD0001558370-24-002475
    FY 2021Yearly · 2021-12-31ProductContract Revenues From Collaborations — Royalty Delivery Of Drug Supplies And Others3,298,000USD0001558370-24-002475
    FY 2021Yearly · 2021-12-31ProductDiscounts And Allowances-18,176,000USD0001558370-24-002475
    FY 2021Yearly · 2021-12-31ProductGovernment Contract10,500,000USD0001558370-24-002475
    FY 2021Yearly · 2021-12-31ProductGross Product81,186,000USD0001558370-24-002475
    Q3 2021Quarterly · 2021-09-30ProductContract Revenues From Collaborations — Development Milestones1,875,000USD0001558370-22-016266
    Q3 2021Quarterly · 2021-09-30ProductContract Revenues From Collaborations — License2,431,000USD0001558370-22-016266
    Q3 2021Quarterly · 2021-09-30ProductContract Revenues From Collaborations — Research And Development Services And Others225,000USD0001558370-22-016266
    Q3 2021Quarterly · 2021-09-30ProductDiscounts And Allowances-4,534,000USD0001558370-22-016266
    Q3 2021Quarterly · 2021-09-30ProductGovernment Contract1,000,000USD0001558370-22-016266
    Q3 2021Quarterly · 2021-09-30ProductGross Product20,546,000USD0001558370-22-016266
    FY 2020Yearly · 2020-12-31ProductDevelopment Milestones2,100,000USD0001558370-23-003035
    FY 2020Yearly · 2020-12-31ProductDiscounts And Allowances-14,774,000USD0001558370-23-003035
    FY 2020Yearly · 2020-12-31ProductGross Product76,470,000USD0001558370-23-003035
    FY 2020Yearly · 2020-12-31ProductLicense40,358,000USD0001558370-23-003035
    FY 2020Yearly · 2020-12-31ProductResearch And Development Services And Others4,467,000USD0001558370-23-003035
    FY 2019Yearly · 2019-12-31ProductContract Revenues From Collaborations — Development Milestones5,500,000USD0001558370-22-002551
    FY 2019Yearly · 2019-12-31ProductContract Revenues From Collaborations — License8,696,000USD0001558370-22-002551
    FY 2019Yearly · 2019-12-31ProductContract Revenues From Collaborations — Research And Development Services And Others1,320,000USD0001558370-22-002551
    FY 2019Yearly · 2019-12-31ProductDiscounts And Allowances-9,310,000USD0001558370-22-002551
    FY 2019Yearly · 2019-12-31ProductGross Product53,082,000USD0001558370-22-002551
    FY 2017Yearly · 2017-12-31ProductContract Revenues From Collaborations — Development Milestones4,234,000USD0001558370-20-001624
    FY 2017Yearly · 2017-12-31ProductContract Revenues From Collaborations — License250,000USD0001558370-20-001624
    FY 2017Yearly · 2017-12-31ProductTavalisse0USD0001558370-20-001624

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.